Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma


| Source: Iovance Biotherapeutics, Inc.

Priority Review Granted with
Prescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023

First Potential Approval of an Individualized, One-Time Cell Therapy
for Patients with Advanced Melanoma